GC
BSX icon

Grimes & Company’s Boston Scientific BSX Stock Holding History

Grimes & Company’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Sell
8,236
-422
-5% -$22.9K 0.01% 361
2026
Q1 		$543K Sell
8,658
-21,550
-71% -$1.72M 0.02% 298
2025
Q4 		$2.88M Buy
30,208
+5,799
+24% +$569K 0.07% 163
2025
Q3 		$2.38M Buy
24,409
+15,947
+188% +$1.65M 0.06% 171
2025
Q2 		$909K Sell
8,462
-100
-1% -$10.1K 0.02% 219
2025
Q1 		$864K Sell
8,562
-4,381
-34% -$441K 0.03% 197
2024
Q4 		$1.16M Buy
12,943
+4,951
+62% +$436K 0.03% 186
2024
Q3 		$670K Buy
7,992
+80
+1% +$6.31K 0.02% 211
2024
Q2 		$609K Sell
7,912
-211
-3% -$15.4K 0.02% 206
2024
Q1 		$556K Buy
8,123
+144
+2% +$9.26K 0.02% 218
2023
Q4 		$461K Sell
7,979
-122
-2% -$6.51K 0.02% 225
2023
Q3 		$428K Sell
8,101
-1
-0% -$52 0.02% 215
2023
Q2 		$438K Sell
8,102
-2
-0% -$104 0.02% 217
2023
Q1 		$405K Buy
8,104
+103
+1% +$4.85K 0.02% 218
2022
Q4 		$370K Buy
8,001
+55
+0.7% +$2.38K 0.02% 226
2022
Q3 		$308K Buy
7,946
+4
+0.1% +$160 0.02% 220
2022
Q2 		$296K Hold
7,942
– – 0.01% 223
2022
Q1 		$352K Sell
7,942
-156
-2% -$6.76K 0.02% 225
2021
Q4 		$344K Sell
8,098
-2,352
-23% -$98.8K 0.02% 228
2021
Q3 		$453K Buy
10,450
+85
+0.8% +$3.76K 0.02% 204
2021
Q2 		$443K Sell
10,365
-495
-5% -$20.8K 0.02% 204
2021
Q1 		$420K Sell
10,860
-495
-4% -$18.7K 0.02% 202
2020
Q4 		$408K Sell
11,355
-495
-4% -$17.8K 0.02% 197
2020
Q3 		$453K Sell
11,850
-459
-4% -$17.7K 0.03% 186
2020
Q2 		$432K Sell
12,309
-9,053
-42% -$326K 0.03% 184
2020
Q1 		$697K Buy
21,362
+963
+5% +$37.6K 0.06% 133
2019
Q4 		$922K Buy
20,399
+10,945
+116% +$458K 0.06% 137
2019
Q3 		$385K Sell
9,454
-935
-9% -$39.6K 0.03% 188
2019
Q2 		$447K Sell
10,389
-595
-5% -$22.9K 0.03% 178
2019
Q1 		$422K Buy
10,984
+505
+5% +$19.3K 0.03% 176
2018
Q4 		$370K Buy
10,479
+426
+4% +$15.4K 0.04% 171
2018
Q3 		$387K Hold
10,053
– – 0.03% 179
2018
Q2 		$329K Sell
10,053
-300
-3% -$9.05K 0.03% 186
2018
Q1 		$283K Hold
10,353
– – 0.03% 188
2017
Q4 		$257K Sell
10,353
-1,990
-16% -$54.9K 0.02% 186
2017
Q3 		$360K Buy
12,343
+50
+0.4% +$1.38K 0.04% 155
2017
Q2 		$341K Hold
12,293
– – 0.04% 156
2017
Q1 		$306K Sell
12,293
-100
-0.8% -$2.43K 0.03% 163
2016
Q4 		$268K Buy
12,393
+3,898
+46% +$85.1K 0.03% 172
2016
Q3 		$202K Buy
+8,495
New +$203K 0.03% 187
2015
Q1 		– Sell
-11,796
Closed -$156K – 167
2014
Q4 		$156K Sell
11,796
-3,729
-24% -$47.7K 0.04% 150
2014
Q3 		$183K Sell
15,525
-2,492
-14% -$31.4K 0.05% 148
2014
Q2 		$230K Buy
18,017
+417
+2% +$5.42K 0.06% 137
2014
Q1 		$238K Buy
17,600
+1,304
+8% +$17.1K 0.07% 127
2013
Q4 		$196K Hold
16,296
– – 0.06% 132
2013
Q3 		$191K Buy
16,296
+2,958
+22% +$32K 0.06% 127
2013
Q2 		$124K Buy
+13,338
New +$113K 0.05% 117

Other funds holding BSX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
ATO
Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
MF
Milford Funds Auckland $6.14B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.66B AUM 33.26% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Grimes & Company's BSX Position: Q2 2026 in Review

Grimes & Company reduced its Boston Scientific (BSX) stake by 4.9% in Q2 2026, selling an estimated $22.9K and leaving 8,236 shares worth $352K. The position accounts for 0.01% of the portfolio, ranked #361.

Grimes & Company first reported a position in BSX in Q2 2013 and has held it in 47 quarters since. The position peaked at $2.88M in Q4 2025. 495 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Grimes & Company held 8,236 shares of Boston Scientific worth $352K as of Q2 2026.
  • Grimes & Company sold 422 Boston Scientific shares in Q2 2026, an estimated $22.9K.
  • Boston Scientific made up 0.01% of Grimes & Company's portfolio in Q2 2026, its #361 holding.
  • Grimes & Company first reported a position in Boston Scientific in Q2 2013 and has held it in 47 quarters since.
  • Grimes & Company's Boston Scientific position peaked at $2.88M in Q4 2025.
  • 495 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.